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EscalationAbstract Aim: The Cher-LOB randomised phase II study showed that the combination of
lapatinib-trastuzumab plus chemotherapy increases pathologic complete response (pCR) rate
compared with chemotherapy plus either trastuzumab or lapatinib. Here, we report the post
hoc survival analysis as per treatment arm, pCR and biomarkers.
Methods: The Cher-LOB study randomised 121 patients with human epidermal growth factor
receptor 2epositive, stage IIeIIIA breast cancer. A specific protocol to collect recurrence-free
survival (RFS) and overall survival (OS) data was designed. Tumour-infiltrating lymphocytes
(TILs) and PAM50-intrinsic subtyping were evaluated at baseline.
Results: At 9-year median follow-up, a trend towards RFS improvement with lapatinib-
trastuzumab over trastuzumab was observed (hazard ratio [HR] 0.44, 95% confidence interval
[CI] 0.18e1.05). Combining treatment arms, pCR was significantly associated with both RFS
(HR 0.12, 95% CI 0.03e0.49) and OS (HR 0.12, 95% CI 0.03e0.49). TILs were significantly
associated with RFS (HR Z 0.978 for each 1% increment). Luminal-A subtype was a signif-
icant and independent predictor of improved RFS as compared with other PAM50-based
intrinsic subtypes at the multivariate analysis including the most relevant clinicopathologic
variables (HR 0.29, 95% CI 0.09e0.94, p Z 0.040).
Conclusions: Cher-LOB trial survival analysis confirmed the prognostic role of pCR and
TILs and showed a signal for a better outcome with lapatinib-trastuzumab over trastuzumab.
Trial registration: NCT00429299.
ª 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human epidermal growth factor receptor 2 (HER2) is
overexpressed/amplified in around 20% of early breast
cancers (BCs) and, in the absence of targeted treatment,
represents a poor prognostic factor.
Over the past three decades, the implementation of
HER2-targeted treatments has progressively improved
the prognosis of HER2-positive BC [1e3]. The neo-
adjuvant model represents an ideal platform to evaluate
new therapeutic strategies, and the adoption of patho-
logic complete response (pCR) as a surrogate end-point
in neoadjuvant trials with regulatory intent is currently
endorsed by US Food and Drug Administration (FDA)
[4]. Indeed, irrespective of tumour biology and disease
stage at diagnosis, patients achieving pCR have a better
outcome than patients with residual disease [5]. In the
neoadjuvant setting, the addition of trastuzumab to
chemotherapy has been associated with a significant
increase in pCR rates over chemotherapy alone and also
with an improved outcome [6e8]. Therefore, several
studies testing different strategies have been set up, with
the primary aim of increasing pCR rate. In particular,
dual HER2-blockade with trastuzumab and lapatinib
provided meaningful clinical results. As compared with
chemotherapy and trastuzumab, the combination of
trastuzumab-lapatinib and chemotherapy was associ-
ated with an increased pCR rate in several randomised
trials [9e13], thus providing evidence supporting the
incorporation of this escalated approach in the neo-
adjuvant management of HER2-positive disease.However, the surrogacy of pCR for drug efficacy is still
object of extensive debate. Indeed, in the above-
mentioned FDA-promoted CTNeoBC meta-analysis [5],
authors failed to formally establish a trial-level rela-
tionship between pCR differences between treatment
arms and survival. Emblematically, although a trend
towards increased survival rates has been consistently
observed with dual versus single HER2-blockade across
escalated neoadjuvant trials, only the CALGB 40601
phase III trial so far reported a significant improvement
in survival outcomes [9,10].
We previously reported findings from the phase II
non-comparative randomised Cher-LOB trial, showing
a relative 80% increase in pCR rates (ypT0is/N0) in
patients treated with lapatinib plus trastuzumab plus
chemotherapy versus chemotherapy plus either lapatinib
or trastuzumab [13].
Here, we report the post hoc analysis of long-term
survival outcomes (recurrence-free survival, RFS; over-
all survival, OS) from the Cher-LOB trial, as per treat-
ment arms, pCR status and biomarkers.
2. Methods
2.1. Cher-LOB study design, patients and study
procedures
The Cher-LOB study design, procedures and primary
efficacy results have been previously published and are
detailed in Supplementary Methods [13e15]. Briefly,
121 patients with stage IIeIIIA HER2-positive BC were
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anthracyclineebased neoadjuvant chemotherapy plus
trastuzumab (arm A), lapatinib (arm B) or concomitant
trastuzumab plus lapatinib (arm C). Ethical Committees
of participating sites approved the study, and informed
consent was obtained from patients before study entry.
pCR was defined as the absence of residual invasive
tumour in breast and axillary nodes. Methodology used
to evaluate tumour-infiltrating lymphocytes (TILs) and
PAM50 intrinsic subtyping [14,15] is detailed in
Supplementary Methods.
2.2. Outcomes
A specific protocol to continue survival data collection
of patients enrolled in the Cher-LOB trial was approved
by participating centers’ institutional review boards.
RFS was calculated from randomisation to BC
recurrence (locoregional or distant; contralateral BC
excluded) or death from any cause, whichever first. OS
was calculated from randomisation to death from any
cause or last follow-up. Patients without an event were
censored at time of the last clinical assessment.
2.3. Statistical analysis
The Kaplan-Meier method was adopted to estimate
survival curves and 5-year rates, whereas the Cox pro-
portional hazard model was used to compare RFS and
OS among subgroups. We examined the relationship
between survival end-points and treatment arm, patho-
logic response at surgery (pCR vs no-pCR), oestrogen
receptor (ER) status and biomarkers (TILs, PAM50-
based intrinsic subtyping). The association between RFS
and biomarkers was evaluated at univariate and multi-
variate analyses. Hazard ratios (HRs) and 95% confi-
dence intervals (CIs) were also reported. All tests were
two-sided and significant for P  0.05. Statistical ana-
lyses were performed using SPSS v.26.
Because the Cher-LOB trial was not designed or
powered to detect treatment differences with respect to
survival end-points, RFS and OS analyses are to be
considered for descriptive purposes only.
3. Results
In the Cher-LOB trial, 36, 39 and 46 patients were
randomly assigned to trastuzumab (A), lapatinib (B)
and concomitant trastuzumab plus lapatinib (C) arms,
respectively. Patients’ clinicopathologic features have
been previously reported [13].
Survival data were available for 114 of the 121 pa-
tients originally included in the Cher-LOB trial (CON-
SORT chart in Supplementary Fig. S1). Patient
characteristics were in line with the overall Cher-LOB
study cohort, as shown in Table 1. Distribution per
arm was as follows: 36 in arm A, 35 in arm B and 43 inarm C. Patient clinicopathologic features as per treat-
ment arm are summarised in Table 2. pCR was observed
in 37 patients (32%).
At a median follow-up of 9 years (95% CI 8.4e9.7),
32 RFS events and 15 deaths were recorded. Patients
experiencing an RFS event were 14 (39%), 10 (29%) and
8 (19%) in the trastuzumab, lapatinib or concomitant
trastuzumab plus lapatinib arm, respectively. Patterns of
first recurrence and causes of death as per treatment arm
are reported in Supplementary Table I. The 5-year RFS
was 77.8% in the trastuzumab arm, 77.1% in the lapa-
tinib arm and 85.8% in the combination arm (Fig. 1A).
RFS was not statistically different among the three
treatment arms (log rank P Z 0.162); however, a trend
towards a benefit for the combination as compared with
the trastuzumab arm (HR 0.44, 95% CI 0.18e1.05) was
observed. Globally, the 5-year RFS was 77.5% for pa-
tients treated with chemotherapy plus single HER2-
blockade (A þ B) and 85.8% for patients treated with
chemotherapy plus dual HER2-blockade (C) (HR 0.52,
95% CI 0.23e1.15; log-rank P Z 0.102; Fig. 1B). There
were no significant differences in RFS as per ER
expression (5-year RFS 79.8% vs 81.1% for ER-negative
and ER-positive tumours, respectively; HR 1.032, 95%
CI 0.50e2.11; log-rank P Z 0.932).
Patients experiencing an OS event were 5 (14%), 4
(11%) and 6 (14%) in the trastuzumab, lapatinib or
concomitant trastuzumab plus lapatinib arm, respec-
tively. No significant difference was observed in OS
between the combination and the trastuzumab arm (HR
1.00, 95% CI 0.31e3.27).
Combining treatment groups, a significant associa-
tion between pCR and RFS was observed. Patients
achieving pCR had a significantly higher 5-year RFS
(97.3%) than those without pCR (72.7%) (HR 0.12, 95%
CI 0.03e0.49; log-rank P < 0.001; Fig. 2A). Results
were consistent in the ER-negative (5-year RFS in pCR
vs no-pCR: 94.7% vs 69.2%, HR 0.11, 95% CI
0.01e0.85; log-rank P Z 0.010) and ER-positive (5-year
RFS in pCR vs no-pCR: 100% vs 74.5%, HR 0.12, 95%
CI 0.02e0.90; log-rank P Z 0.014) cohorts separately.
Patients achieving pCR also presented a significantly
higher 5-year OS (97.2% vs 89.5%) than those without
pCR (HR 0.12, 95% CI 0.03e0.49; log-rank P Z 0.028;
Fig. 2B).
Finally, the impact of tumour biology and microen-
vironment on RFS was assessed.
Baseline stromal TIL (strTIL) evaluation was avail-
able for 102 of 114 patients assessable for the long-term
outcome and significantly correlated with RFS at uni-
variate analysis: an HR of 0.978 for each 1%
TIL increment was observed (95% CI 0.957e0.999,
P Z 0.041). At multivariate analysis including strTILs,
pCR, clinical stage, treatment arm (single versus dual
HER2-blockade), ER status and age, only pCR main-
tained a significant association with RFS, as shown in
Supplementary Table 2.
Table 1
Clinicopathological characteristics of patients included in the survival analysis compared with the overall CherLOB population.
Variable Overall CherLOB population Survival analysis population
N (%) Mean (range) IQ (Q1; Q3) N (%) Mean (range) IQ (Q1; Q3) p
Age
Available 121 (100) 49 (26e68) 12 (44e56) 114 (100) 49 (26e68) 13 (44e57) ns
Missing 0 (0)
Clinical stage
IIA 38 (31.4) 37 (32.5) ns
IIB 61 (50.4) 57 (50.0)
IIIA 22 (18.2) 20 (17.5)
Missing 0 (0) 0 (0)
Histotype
Ductal 115 (95) 108 (94.7) ns
Lobular 6 (5) 6 (5.3)
NA 0 (0) 0 (0)
Grade
1e2 23 (19) 19 (16.7) ns
3 77 (63.9) 74 (64.9)
Missing 21 (17.4) 21 (18.4)
ER
ER- 50 (41.3) 45 (39.5) ns
ERþ 71 (58.7) 69 (60.5)
Missing 0 (0) 0 (0)
Ki67
Available 113 (93.4) 29.6 (4e90) 15 (20e35) 107 (93.8) 29.5 (4e90) 15 (20e35) ns
Missing 8 (6.6) 7 (6.2)
Arm
A (CT þ T) 36 (29.8) 36 (31.5) ns
B (CT þ L) 39 (32.2) 35 (30.7)
C (CT þ T þ L) 46 (38) 43 (37.8)
Missing 0 (0) 0 (0)
strTILs
Available 105 (86.8) 26.8 (0e100) 31 (9e40) 102 (89.5) 26.8 (0e100) 30.5 (9.5e40) ns
Missing 16 (13.2) 12 (10.5)
PAM50
Luminal A 23 (19.0) 21 (18.5) ns
Luminal B 14 (11.6) 14 (12.3)
HER2-enriched 22 (18.2) 22 (19.3)
Basal-like 12 (9.9) 12 (10.5)
Normal-like 15 (12.4) 15 (13.1)
Missing 35 (28.9) 30 (26.3)
N, number; IQ, interquartile; Q, quartile; P, P-value; ER, oestrogen receptor; CT, chemotherapy; T, trastuzumab; L, lapatinib; strTILs, stromal
tumour infiltrating lymphocytes; ns, non-significant.
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114 patients included in the long-term outcome analysis.
Subtype distribution was as follows: HER2-
enriched Z 26.2% (N Z 22), luminal A Z 25.0%
(N Z 21), luminal B Z 16.7% (N Z 14), basal-
like Z 14.3% (N Z 12) and normal-like Z 17.9%
(N Z 15). Excluding normal-like cases, no significant
difference in RFS as per PAM50 intrinsic subtyping was
observed (evaluable N Z 69; Supplementary Fig. S2);
however, at multivariate analysis including PAM50
subtypes (luminal A versus other subtypes), pCR, clin-
ical stage, treatment arm (single versus dual HER2-
blockade), ER status and age, both pCR and luminal A
subtype (as compared with other PAM50 subtypes) were
confirmed to retain an independent prognostic value, as
shown in Table 3.4. Discussion
Findings from the post hoc survival analysis of the
phase II randomised Cher-LOB trial regarding the
prognostic role of pCR in patients with HER2-positive
BC receiving neoadjuvant chemotherapy plus anti-
HER2 treatment are consistent with previous reports.
By combining treatment arms, we showed that achieving
pCR was highly and significantly associated with long-
term survival. Patients with pCR experienced a 78%
relative decrease in the risk of an RFS or OS event at 5
years as compared with those with residual invasive
disease. This supports the strong prognostic role that the
achievement of pCR retains in HER2-positive BC at a
single-patient level, as already highlighted in the context
of the CtNeoBC meta-analysis [5] and in studies testing
Table 2
Clinicopathological characteristics of patients included in the survival analysis as per the treatment arm.
Variable Arm A (CT þ T) Arm B (CT þ L) Arm C (CT þ T þ L)
N (%) Mean (range) IQ (Q1; Q3) N (%) Mean (range) IQ (Q1; Q3) N (%) Mean (range) IQ (Q1; Q3)
Number of patients 36 35 43
Age
Available 36 (100) 50 (34e65) 13 (44e57) 35 (100) 49 (34e68) 13 (43e56) 43 (100) 48 (26e65) 13 (43e56)
Missing 0 (0) 0 (0) 0 (0)
Clinical stage
IIA 11 (30.6) 13 (37.1) 13 (30.2)
IIB 19 (52.8) 17 (48.6) 21 (48.8)
IIIA 6 (16.7) 5 (14.3) 9 (20.9)
Missing 0 (0) 0 (0) 0 (0)
Histotype
Ductal 32 (88.9) 33 (94.3) 43 (100)
Lobular 4 (11.1) 2 (5.7) 0 (0)
NA 0 (0) 0 (0) 0 (0)
Grade
1e2 8 (22.3) 4 (11.4) 7 (16.3)
3 24 (66.7) 23 (65.7) 27 (62.8)
Missing 4 (11.1) 8 (22.9) 9 (20.9)
ER
ER- 16 (44.4) 12 (34.3) 17 (39.5)
ERþ 20 (55.6) 23 (65.7) 26 (60.5)
Missing 0 (0) 0 (0) 0 (0)
Ki67
Available 34 (94.4) 26.8 (10e60) 13.5 (17.7e31.2) 33 (94.3) 29.3 (12e65) 16.5 (20e36.5) 40 (93) 32.1 (4e90) 20 (20e40)
Missing 2 (5.6) 2 (5.7) 3 (7)
pCR
Yes 9 (25) 9 (25.7) 19 (44.2)
No 27 (750,029) 26 (74.3) 24 (55.8)
N, number; IQ, interquartile; Q, quartile; ER, oestrogen receptor; CT, chemotherapy; T, trastuzumab; L, lapatinib; pCR, pathological complete
response.
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approach [7,9,16e18]. Importantly, the positive prog-
nostic impact of pCR observed in our analysis was
consistent in both ER-positive and ER-negative sub-
groups, in line with previous evidence [5,16e19].
Although the Cher-LOB trial was not powered to
formally detect survival differences across treatment
arms, we confirmed the trend towards improved survival
with the combination of lapatinib plus trastuzumab over
single HER2-blockade. In the CALGB 40601 phase IIIFig. 1. Kaplan-Meier RFS curves as per A. treatment arm (ch
chemotherapy þ trastuzumab þ lapatinib) and B. dual HER2 blockade
arms combined). RFS, recurrence-free survival; CI, confidence interva
growth factor receptor 2.trial, a notable 68% and 66% relative improvement in
the 7-year RFS and OS rates, respectively, was reported
with lapatinib plus trastuzumab as compared with the
trastuzumab single agent [9]. In addition, consistent with
our findings, in both the NSABP B41 and NeoALTTO
trials, a numerical increase in long-term survival rates
with dual HER2-targeting was observed [16,17].
Correlative studies regarding the association between
survival and tumour microenvironment and biology in
the context of the Cher-LOB study were also performed.emotherapy þ trastuzumab vs chemotherapy þ lapatinib vs
vs single HER2 blockade (CT þ trastuzumab and CT þ lapatinib
l; HR, hazard ratio; CT, chemotherapy; HER2, human epidermal
Fig. 2. Kaplan-Meier curves by pCR. A. RFS curve; B. OS curve. RFS, recurrence-free survival; CI, confidence interval; HR, hazard ratio;
pCR, pathological complete response; OS, overall survival.
Table 3
Multivariate analysis for RFS including PAM50 subtypes (luminal-A
versus other subtypes), pCR, clinical stage (IIA vs IIB vs IIIA),
treatment arm (single versus dual HER2-blockade), ER status (posi-
tive versus negative) and age (continuous variable).
Variable HR (95% CI) p
PAM50
Luminal-A vs other 0.29 (0.09e0.94) 0.040
Pathologic response
pCR vs no pCR
0.09 (0.01e0.77) 0.027
Clinical stage
Stage IIA 0.65 (0.16e2.70) 0.554
Stage IIB 0.84 (0.22e3.27) 0.806
Stage IIIA ref 0.810
Treatment arm
Dual vs single HER2-blockade 0.83 (0.32e2.18) 0.711
ER status
Positive vs negative 1.69 (0.61e4.73) 0.314
Age (cont.) 0.99 (0.95e1.04) 0.863
p values < 0.05 are highlighted in bold. RFS, recurrence-free survival;
CI, confidence interval; HR, hazard ratio; HER2, human epidermal
growth factor receptor 2; cont, continuous; vs, versus; pCR, pathologic
complete response; ER, oestrogen receptor.
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higher baseline TIL levels and pCR in the Cher-LOB
trial. Here, we found baseline TILs to be prognostic in
the overall Cher-LOB study population. In particular,
similar to the findings of the NeoALTTO translational
analysis [20], each 1% TIL increase corresponded to a
2.2% decrease in the risk of an RFS event across treat-
ment groups. These results are further supported by a
pooled analysis assessing the prognostic role of TILs as
per BC subtype [21]. Indeed, among 1379 patients with
HER2-positive BC undergoing neoadjuvant chemo-
therapy (the majority also receiving anti-HER2 treat-
ment), a positive association between TILs and disease-
free survival was detected. Our findings therefore add
further evidence in support to the clinical validity of
TILs as a prognostic biomarker in HER2-positive early
BC [20e25]. Importantly, TIL evaluation is currently
endorsed by both European Society for Medical
Oncology guidelines [26] and World Health Organisa-
tion Classification of Tumours, 5th edition, (http://
publications.iarc.fr) in this setting.
Besides TILs, PAM50-based intrinsic subtyping is
gaining increasing clinical relevance in HER2-positive
disease. We previously reported that HER2-enriched
and luminal A subtypes account for most of the Cher-
LOB study population (HER2-enriched Z 26.2%,
luminal A Z 25%), with the first being associated with
the highest (50%) and the second with the lowest (21%)
pCR rate [14]. In the present work, no significant asso-
ciation was identified between RFS and intrinsic sub-
types. However, the luminal A phenotype was
significantly and independently associated with longer 5-
year RFS than other PAM50 subtypes, and this is
consistent with the CALGB 40601 translational anal-
ysis, where, similarly, patients with luminal A BC
showed the lowest pCR rate (14.3%) while experiencing
the most favourable long-term outcome as compared
with other subtypes (no RFS events at 7 years) [9]. The
notion that the luminal A phenotype exhibits a lower
degree of sensitivity to chemotherapy plus HER2-
blockade while retaining a positive impact on
survival apparently challenges the prognostic value ofpCR. However, this is an example of so-called Simp-
son’s paradox [27,28], describing the confounding
impact of unmeasured, but causal, variables on associ-
ations, which translates into an inverse relationship be-
tween chemosensitiveness and prognosis in case of
residual disease after neoadjuvant treatment. Consis-
tently, although pCR is prognostic in all traditionally
defined BC subtypes (hormone receptorepositive/
HER2-negative, HER2-positive and triple-negative),
this association is stronger in most chemosensitive sub-
groups, namely triple-negative and HER2-positive.
These observations [7,9,16,29,30] suggest that even
among patients with HER2-positive BC, PAM50 anal-
ysis may add a further layer of stratification, beyond
hormone receptor status [31]. Indeed, PAM50 analysis
may allow controlling for those causal variables poten-
tially affecting the strength of the association between
pCR and prognosis and which would otherwise dilute
the observed prognostic impact of pCR itself. Our
findings therefore emphasise that this source of
V. Guarneri et al. / European Journal of Cancer 153 (2021) 133e141 139heterogeneity within HER2-positive BC should be taken
into consideration when designing future neoadjuvant
trials.
The neoadjuvant platform, albeit endorsed by the FDA
[32] for the evaluation of investigational interventions given
the more favourable cost-effective balance as compared
with the adjuvant setting, can be underpowered to
demonstrate significant survival differences across treat-
ment arms. Indeed, the sample size required to capture
meaningful pCR differences is significantly smaller than
that required to detect significant survival differences.
Indeed, although nearly all the trials comparing the com-
bination of trastuzumab þ lapatinib versus trastuzumab
alone (in association with chemotherapy) for the neo-
adjuvant management of HER2-positive breast cancer re-
ported a substantial improvement in pCR rates with the
dual HER2 targeting strategy as compared with single
HER2-blockade [9e13], many of them, with the exception
of the CALGB 40601 trial [9], failed to demonstrate a sta-
tistically significant improvement in survival end-points.
However, theywere all consistent in confirming the positive
prognostic impact of pCR at a single-patient level
[5,7,9,16e18]. Overall, these observations suggest that such
lack of survival improvement with dual over single HER2-
blockade may reflect a statistical limitation, rather than a
real absence of long-term advantage.
For this reason, although possibly limited by the rela-
tively small sample size, long-term survival results from the
Cher-LOB study are worthy of attention because they add
further evidence in the same direction as that provided by
other neoadjuvant studies of dual HER2-blockade.
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